Stone GW， Ware JH， Bertrand ME， Lincoff AM， Moses JW， Ohman EM， White HD， Feit F， Colombo A， McLaurin BT， Cox DA， Manoukian SV， Fahy M， Clayton TC， Mehran R， Pocock SJ; ACUITY Investigators.
    Columbia University Medical Center and the Cardiovascular Research Foundation， New York， New York 10022， USA. gs2184@columbia.edu
Abstract
    CONTEXT: At 30-day follow-up， patients with moderate- and high-risk acute coronary syndromes (ACS) undergoing early invasive treatment in the ACUITY trial with bivalirudin monotherapy vs heparin plus glycoprotein (GP) IIb/IIIa inhibitors had noninferior rates of adverse ischemic events with reduced rates of major bleeding. Deferred upstream use of GP IIb/IIIa inhibitors for selective administration to patients undergoing percutaneous coronary intervention (PCI) resulted in a significant reduction in major bleeding， although a small increase in composite ischemia could not be excluded.
OBJECTIVE: To determine 1-year ischemic outcomes for patients in the ACUITY trial.
    DESIGN， SETTING， AND PATIENTS: A prospective， randomized， open-label trial with 1-year clinical follow-up at 450 academic and community-based institutions in 17 countries. A total of 13，819 patients with moderate- and high-risk ACS undergoing invasive treatment were enrolled between August 23， 2003， and December 5， 2005.
    INTERVENTIONS: Patients were assigned to heparin plus GP IIb/IIIa inhibitors (n = 4603)， bivalirudin plus GP IIb/IIIa inhibitors (n = 4604)， or bivalirudin monotherapy (n = 4612). Of these patients， 4605 were assigned to routine upstream GP IIb/IIIa administration and 4602 were deferred to selective GP IIb/IIIa inhibitor administration.
MAIN OUTCOME MEASURE: Composite ischemia (death， myocardial infarction， or unplanned revascularization for ischemia) at 1 year.
    RESULTS: Composite ischemia at 1 year occurred in 15.4% of patients assigned to heparin plus GP IIb/IIIa inhibitors and 16.0% assigned to bivalirudin plus GP IIb/IIIa inhibitors (compared with heparin plus GP IIb/IIIa inhibitors， HR， 1.05; 95% CI， 0.95-1.16; P = .35)， and 16.2% assigned to bivalirudin monotherapy (HR， 1.06; 95% CI， 0.95-1.17; P = .29). Mortality at 1 year occurred in an estimated 3.9% of patients assigned to heparin plus GP IIb/IIIa inhibitors， 3.9% assigned to bivalirudin plus GP IIb/IIIa inhibitors (HR， 0.99; 95% CI， 0.80-1.22; P = .92)， and 3.8% assigned to bivalirudin monotherapy (HR， 0.96; 95% CI， 0.77-1.18; P = .67). Composite ischemia occurred in 16.3% of patients assigned to deferred use compared with 15.2% of patients assigned to upstream administration (HR， 1.08; 95% CI， 0.97-1.20; P = .15).
    CONCLUSIONS: At 1 year， no statistically significant difference in rates of composite ischemia or mortality among patients with moderate- and high-risk ACS undergoing invasive treatment with the 3 therapies was found. There was no statistically significant difference in the rates of composite ischemia between patients receiving routine upstream administration of GP IIb/IIIa inhibitors vs deferring their use for patients undergoing PCI.